Summary
Significant differences in the content of iron (III) and total iron were found in post mortem substantia nigra of Parkinson's disease. There was an increase of 176% in the levels of total iron and 255% of iron (III) in the substantia nigra of the parkinsonian patients compared to age matched controls. In the cortex (Brodmann area 21), hippocampus, putamen, and globus pallidus there was no significant difference in the levels of iron (III) and total iron. Thus the changes in total iron, iron (III) and the iron (II)/iron (III) ratio in the parkinsonian substantia nigra are likely to be involved in the pathophysiology and treatment of this disorder.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ben-Shachar D, Ashkenazi A, Youdim MBH (1986) The long term consequences of early iron deficiency. Int J Dev Neurosci 4: 81–88
Birkmayer W, Riederer P (1985) Die Parkinson-Krankheit, 2nd edn. Springer, Wien New York
Birkmayer W, Birkmayer JGD (1986) Iron, a new aid in the treatment of Parkinson patients. J Neural Transm 67: 287–292
Carlsson A (1974) The in vivo estimation of rates of tryptophan and tyrosine hydroxylation: effects of alterations in enzyme environment and neuronal activity. In: Wolstenholme GEW, Fitzsimons DW (eds) Aromatic amino acids in the brain. Elsevier, Excerpta Medica, Amsterdam London New York, pp 126–134
Crichton RR (1979) Interaction between iron metabolism and oxygen activation. In: Oxygen free radicals and tissue damage. Ciba Foundation Symposium. Excerpta Medica, Amsterdam, p 57
Dexter DT, Jenner P, Marsden CD (1987 a) Alterations in the content of iron and other metal ions in Parkinsonian brain. Br J Pharmacol 91: P 427
Dexter DT, Wells FR, Agid F, Agid Y, Lees AJ, Jenner P, Marsden CD (1987 b) Increased nigral iron content in postmortem parkinsonian brain. Lancet ii: 1219–1220
Donaldson J, Cloutier T, Minnich JL, Barbeau A (1974) Trace metals and biogenic amines in rat brain. In: McDowell F, Barbeau A (eds) Second Canadian-American Conference on Parkinson's disease. Adv Neurol 5: 245–252
Drayer BP, Olanow W, Burger P, Johnson GA, Herfkens R, Riederer S (1986) Parkinson plus syndrome: diagnosis using high field MR imaging of brain iron. Radiology 159: 493–498
Earle KM (1968) Studies on Parkinson's disease including X-ray fluorescent spectroscopy of formalin fixed brain tissue. J Neuropathol Exp Neurol 27: 1–14
Ehringer H, Hornykiewicz O (1960) Verteilung von Noradrenalin und Dopamin im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Wien Klin Wochenschr 38: 1236–1239
Fischer PA, Schneider E, Jacobi P (1983) Klinische Bilder des Parkinson-Syndroms und ihre Verläufe. In: Gänshirt H, Berlit P, Haack G (eds) Pathophysiologie, Klinik und Therapie des Parkinsonismus. Editiones “Roche”, Basle, pp 51–65
Greiner AC, Chan SC, Nicolson GA (1975) Human brain contents of calcium, copper, magnesium, and zinc in some neurological pathologies. Clin Chim Acta 64: 211–213
Halliwell B, Gutteridge JMC (1985) Free radicals in biology and medicine. Calendon Press, Oxford
Ikeda M, Levitt M, Udenfriend S (1965) Hydroxylation of phenylalanine by purified preparations of adrenal and brain tyrosine hydroxylase. Biochem Biophys Res Commun 18: 482–488
Kaufman S (1977) Mixed function oxygenases—general considerations. In: Usdin E, Weiner N, Youdim MBH (eds) Structure and function of monoamine enzymes. Marcel Dekker Inc., New York Basle, pp 3–22
Lloyd KG, Davidson L, Hornykiewicz O (1975) The neurochemistry of Parkinson's disease: effect of L-DOPA therapy. J Pharmacol Exp Ther 195: 453–464
Nagatsu T, Kato T, Numata Y, Ihuta K, Sano M, Nagatsu I, Kondo Y, Inagaki S, Ilzuka R, Hori A, Narabayashi H (1977) Phenylethanolamine-N-methyltransferase and other enzymes of catecholamine metabolism in human brain. Clin Chim Acta 75: 221–232
Nagatsu T, Namaguchi T, Koto T, Sugimoto T, Matsuura S, Akino M, Nagatsu I, Iizuka R, Narabayashi H (1981) Biopterin in human brain and urine from controls and parkinsonian patients: application of a new radioimmunoassay. Clin Chim Acta 109: 305
Rausch WD, Hirata Y, Nagatsu T, Riederer P, Jellinger K (1988) Tyrosine hydroxylase activity in caudate nucleus from Parkinson's disease. Effects of iron and phosphorylating agents. J Neurochem 50: 202–208
Riederer P, Rausch WD, Birkmayer W, Jellinger K, Seemann D (1978) CNS modulation of adrenal tyrosine hydroxylase in Parkinson's disease and metabolic encephalopathies. J Neural Transm [Suppl] 14: 121–131
Riederer P, Sofic E, Rausch WD, Kruzik P, Youdim MBH (1985) Dopaminforschung heute und morgen — L-DOPA in der Zukunft. In: Riederer P, Umek H (eds) L-DOPA-Substitution der Parkinson-Krankheit. Springer, Wien New York, pp 127–144
Riederer P, Sofic E, Rausch WD, Schmidt B, Youdim MBH (1988 a) Transition metals, ferritin, glutathione and ascorbic acid in Parkinsonian brains. J Neurochem, in press
Riederer P, Rausch WD, Schmidt B, Kruzik P, Konradi C, Sofic E, Danielczyk W, Fischer M, Ogris E (1988 b) Biochemical fundamentals of Parkinson's disease. Mount Sinai J Med 55: 21–28
Rutledge JN, Hilal SK, Silver AJ, Defendini R, Fahn S (1987) Study of movement disorders and brain iron by MR. Am J Neuroradiol 8: 397–411
Siedel J, Wahlefeld AW, Ziegenhorn J (1984) Improved, ferrozine-based reagent for the determination of serum iron (transferrin iron) without deproteinisation. Clin Chem 30: 975
Switzer III RC (1982) Iron-rich areas of brain as targets for damage in certain induced and naturally occuring neurological disorders. In: Saltman P, Hegenauer J (eds) The biochemistry and physiology of iron. Elsevier, Amsterdam, pp 569–574
Spatz H (1922) Über den Eisennachweis im Gehirn, besonders in Zentren des extrapyramidal-motorischen Systems. Z Ges Neurol Psychiat 77: 261–390
Ule G, Völkl A, Berlet H (1974) Spurenelemente im menschlichen Gehirn. Z Neurol 206: 117–128
Völkl A, Ule G (1972) Spurenelemente im menschlichen Gehirn. Z Neurol 202: 331–338
Youdim MBH (1985) Brain iron metabolism: biochemicals and behavioural aspects in relation to dopaminergic neurotransmission. In: Lajtha A (ed) Handbook of neurochemistry, vol 10. Plenum Press, New York, pp 731–755
Youdim MBH (1988) Iron in the brain: implications for Parkinson's and Alzheimer's diseases. Mount Sinai J Med 55: 97–102
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sofic, E., Riederer, P., Heinsen, H. et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neural Transmission 74, 199–205 (1988). https://doi.org/10.1007/BF01244786
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01244786